Multimodality Management of “Borderline Resectable” Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience

BACKGROUND: Pancreatic neuroendocrine tumors (PanNETs) constitute approximately 3% of pancreatic neoplasms. Like patients with pancreatic ductal adenocarcinoma (PDAC), some of these patients present with “borderline resectable disease.” For these patients, an optimal treatment approach is lacking. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambe, Chenwi M., Nguyen, Phuong, Centeno, Barbara A., Choi, Junsung, Strosberg, Jonathan, Kvols, Larry, Hodul, Pamela, Hoffe, Sarah, Malafa, Mokenge P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937248/
https://www.ncbi.nlm.nih.gov/pubmed/28975822
http://dx.doi.org/10.1177/1073274817729076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937248/
https://www.ncbi.nlm.nih.gov/pubmed/28975822
http://dx.doi.org/10.1177/1073274817729076

Ejemplares similares